Bacteriophage Purification via Cesium Chloride Gradient

Comprehensive phage characterization includes: Efficiency of Plating (EOP)—serial dilution to find highest dilution producing confluent lysis; Routine Test Dilution—the highest dilution failing to produce confluent lysis (standard for future testing); Single Step Growth Curve—analyzing sigmoid curves to determine latent period (time to maximum growth rate) and burst size (phages released per cell); Host Range Determination—testing coverage across bacterial species within genus or family; PFGE for genome sizing; Electron microscopy for morphological identification. Different phages show varying lytic activities: clear confluent lysis, opalescent lysis, no reaction, individual plaques, or resistant mutants. Pulse Field Gel Electrophoresis (PFGE) extends DNA sizing beyond standard electrophoresis (0.2-50 kb to 200 bp-12 Mb). Procedure: mix phage suspension with low melting agarose, create plugs, release DNA by overnight shaking at 55°C, wash plugs, perform restriction digestion if needed, load plugs in agarose gel, run at appropriate voltage, stain with ethidium bromide. Transmission Electron Microscopy uses negative staining with uranyl acetate on carbon-coated grids. ~96% of examined phages are tailed phages with characteristic components: head, tail tube, sheath, base plate, spikes, and tail fibers. Different families have distinct morphologies: T4 phages have contractile tails, lambda phages have different tail structures, filamentous phages have long flexible tails. Modern sequencing technologies include Sanger (first generation, ~1000 bp reads), Illumina (next generation, ~300-400 bp fragments requiring assembly), and Nanopore (single-molecule real-time sequencing). Workflow: template preparation, fragmentation, barcoding, PCR amplification, sequencing, and bioinformatics assembly. Coverage of at least 9x ensures reliable reconstruction. Bioinformatics identifies open reading frames (ORFs) coding for structural proteins (capsid/head/tail assembly), enzymes (DNA synthesis), and other functions. Comparative genomics enables species identification and evolutionary analysis.

The bacteriophage plaque assay is a laboratory technique used to determine the concentration (titer) of bacteriophages in a sample by serially diluting the phage stock, mixing each dilution with a bacterial culture (E. coli) in soft agar, pouring onto petri plates, and incubating; the number of clear plaques formed indicates the original phage concentration, with more dilute samples yielding fewer plaques.

Bacteriophage purification involves isolating individual plaques from infected bacterial cultures through repeated rounds of plaque picking, filtration, and serial dilution to obtain a pure phage lysate suitable for titer determination; the process includes dissolving isolated plaques in LB broth, filtering the suspension through a 22-micron syringe filter, preparing serial dilutions (5-7 dilutions), mixing with host bacterial suspension, and pouring onto LB agar plates for overnight incubation at 37°C to visualize clear plaques, with the procedure repeated 4-5 times to achieve high-purity phage preparation.

The plaque assay is a fundamental microbiological technique used to determine the concentration of bacteriophages (such as T4) in a sample by counting clear zones (plaques) formed when phages infect and lyse bacterial cells (E. coli K12 or strain B) on agar plates; each plaque represents one or more phage particles that infected a single host cell, and the titre is calculated by dividing the number of plaques by the dilution factor and volume of sample used, expressed as plaque forming units per milliliter (PFU/mL).

Phage genomic analysis involves extracting phage DNA and sequencing the genome. The process includes: (1) DNA extraction using methods that remove bacterial DNA contamination; (2) Sequencing using platforms like Illumina; (3) Genome assembly to reconstruct the complete phage genome. The JKT1 phage genome is 43,000 base pairs with 53.7% G+C content, containing 57 ORFs (open reading frames), of which 27 are known proteins and 30 are hypothetical proteins.

Bacteriophage isolation involves collecting environmental samples (such as soil from Isabela, Puerto Rico), mixing with liquid solution, incubating in a shaker, and centrifuging. The supernatant is filtered through a 0.22-micrometer filter to isolate bacteriophages from other particles. Two methods exist: direct isolation (immediate plaque assay) and enriched isolation (incubation with host bacteria to increase concentration). Multiple rounds of purification yield clonal populations (genetically identical phages) confirmed by consistent plaque morphology. The purified phage is then named (e.g., 'Cyro') and prepared for genomic analysis. Genomic annotation involves identifying and assigning functions to genes within a phage genome using bioinformatics tools. The process transforms raw DNA sequences into meaningful biological information by identifying open reading frames (ORFs), start codons, and stop codons. Tools like Glimmer generate maps of potential coding regions, while HMMER identifies protein similarities to predict function.

Phage research follows a comprehensive workflow from discovery to application: phages are isolated from diverse sources like soil, water, and sewage; characterized by host range, morphology, and stability; analyzed genomically using high-quality DNA extraction and sequencing technologies (Illumina, PacBio, Oxford Nanopore); studied for their interaction mechanisms (lytic vs. lysogenic cycles) and applications in combating antimicrobial resistance through phage cocktails, engineered phages, and combination therapies with antibiotics; applied across human infection therapy, agriculture, animal farming, wastewater management, and phage display technology for protein development.

Cross-assembly combines metagenomic samples using sequence assembly, then plots coverage depth across samples to identify viral genomes. Genome assembly generates assembly graphs containing valuable information often ignored in standard analysis. FABLES analyzes these graphs to identify individual phage genomes by calculating read coverage, linearizing fragments with different coverage patterns, and deconvoluting complex cases into separate genomes. This reveals complete circular genomes, repetitive sequences used by lysogenic phages for integration, and complex cases with multiple components. Despite good annotation tools, phage genomes still contain many genes with unknown functions. Researchers have developed approaches by linearizing genomes and orienting them so integrase is always at one end, revealing strong conservation in gene order. Long Short-Term Memory (LSTM) models can predict functions based on gene order rather than sequence similarity. AlphaFold predictions can validate these annotations by generating protein structures and comparing them against known structures in databases.

This video demonstrates a laboratory technique for removing endotoxins from concentrated phage lysate by adding octanol, shaking the mixture for one hour, chilling, centrifuging, and collecting the aqueous phase containing the phage; the method can be repeated if initial endotoxin removal is insufficient.

Phage manufacturing follows standardized protocols: bacteria are grown to OD600 0.1-0.6, infected at MOI 0.01, allowed to amplify for 6 hours, then filtered through 0.22 μm filters. Lysates are concentrated using 100 kDa cutoff centrifuge concentrators. Titer is determined via double agar layer method. Endotoxin concentration is measured using Limulus amebocyte lysate (LAL) assay with acceptable limits of ≤5 EU/mL per gig. Sterility testing follows USP 71 guidelines, and exotoxin A levels are tested via Western blot (sensitive to <1 pg/mL). Phages are diluted in PBS with magnesium sulfate to 1×10^10 PFU per dose.

Finding phages that match a patient's specific bacterial isolate is challenging because phages must match the exact strain, not just species. Researchers searched sewage, barnyard waste, and ship bilges worldwide. Multiple phages were needed in cocktails to prevent resistance. Endotoxin purification was critical—requiring specialized weekend work to meet FDA safety thresholds before treatment could proceed.

Phage therapy has continued since the Cold War in Georgia and Central/Eastern Europe. The first regulated randomized double-blind clinical trial was reported in June 2009 in the Journal of Wound Care, evaluating a bacteriophage cocktail for infected venous ulcers. The FDA approved it as a Phase 1 trial, demonstrating safety but not efficacy, with authors noting that standard wound care chemicals (lactoferrin, silver) may have interfered with phage viability. Another trial in August 2009 in Clinical Otolaryngology showed bacteriophage preparations were safe and effective for chronic ear infections caused by Pseudomonas aeruginosa. In 2015, a psychology professor's wife (Stephanie Stradling) used FDA-approved emergency phage treatment for her husband Tom Patterson, who had a resistant Acinetobacter baumannii infection while traveling in Egypt. After three days of treatment at UC San Diego Health, he woke from his coma. Since 2006, the FDA and USDA have approved several phage products: LMP 102 IntraLytx for ready-to-eat poultry and meat, and Listex (developed by Mike Rios) for killing Listeria monocytogenes on cheese, granted GRAS status and approved for all food products in July 2007. In 2011, the FDA cleared the first phage-based diagnostic product: KeyPath MRSA, a blood culture test using phage cocktails to detect Staphylococcus aureus and determine methicillin resistance in 5 hours versus 2-3 days for standard methods. Government agencies in the West have explored phages for counteracting bioweapons and toxins like anthrax and botulism. Other applications include spray application in horticulture for protecting plants from bacterial disease, bio-sites for environmental surfaces in hospitals, and preventative treatments for catheters and medical devices.

Strategies to overcome bacterial resistance include phage cocktails, combinations with antibiotics, genetic engineering, and combining with disinfectants. Phage therapy began in 1917 but declined with antibiotic introduction. Current studies use various administration routes: topical, intravenous, transnasal, intrarectal, transurethral, and oral. A 2022 study compiled 63 successful cases treating infections by Pseudomonas, Klebsiella, Enterococcus. Most cases used phage cocktails at high concentrations (10^6-10^9 phages/mL). Outcomes included clinical cure, reinfection, and rare adverse events. Phage therapy is particularly effective for chronic periprosthetic infections with biofilms. For drug-resistant infections, phages treat ESBL-producing Enterobacteriaceae, carbapenem-resistant Klebsiella pneumoniae, and Pseudomonas aeruginosa. Regulatory bodies recommend phage use for life-threatening infections with no alternatives. Quality control requires verifying phage activity, ensuring absence of resistance/virulence/integration genes, sterility, and endotoxin removal.

Industrial bioprocessing purification employs two primary techniques—chromatography and filtration—to isolate target proteins from complex biological mixtures. Chromatography utilizes column-based separation where resin beads interact with molecules based on physical properties: size-exclusion separates by molecular dimensions, ion-exchange separates by charge, and hydrophobic-interaction chromatography separates by hydrophobicity using high-salt conditions to expose protein patches. Filtration, specifically Tangential Flow Filtration (TFF), separates molecules by size using ultrafiltration membranes, enabling concentration (removing water) and diafiltration (buffer exchange). The purification workflow typically involves pre-filtration, multiple chromatography steps, TFF processing, and final filtration, all managed through batch records with operator verification to ensure product purity and consistency.

Tangential Flow Filtration (TFF) is an advanced membrane-based separation technique that differs from traditional dead-end filtration by having fluid pass across the membrane surface rather than through it, which increases filtration efficiency and extends membrane lifespan; TFF systems are highly scalable, ranging from 0.1 to 65 square meters of filtration surface area, and can be configured for either single-use or multi-use applications with automated process control, making them versatile for both defiltration and concentration processes in biomolecule purification.

A two-column purification process using mixed-mode chromatography (Nuvia cPrime) followed by anion exchange chromatography (Nuvia Q) effectively purifies recombinant adenoviruses for clinical applications, achieving high yield, low host-cell protein and DNA contamination, and scalable manufacturing suitable for producing clinical-grade viral vectors.

Monolith chromatography provides scalable purification solutions for lipid nanoparticles across all manufacturing scales. The O column can capture particles directly after encapsulation with inline dilution, removing free nucleic acids and enriching encapsulation efficiency. Elution in formulation buffer concentrates particles with buffer exchange and purification from free nucleic acids. This shearless process imparts minimal stress on particles, preserving particle integrity. Dynamic binding capacity of 3.7 mg encapsulated RNA per milliliter of column volume enables scaling from analytical (0.1 ml) to production (40 liter) scales while maintaining consistent process parameters.